Literature DB >> 2347477

Hepatitis B virus replication in patients with chronic liver diseases.

B M Gandhi1, M Irshad, S K Acharya, Y K Joshi, B N Tandon.   

Abstract

One hundred and seventy five subjects with chronic liver diseases which included patients with chronic active hepatitis (90), liver cirrhosis (31) and asymptomatic hepatitis B carriers (54), were included in the study. Hepatitis B virus (HBV) specific DNA-polymerase activity and HBe-markers were tested as markers of HBV-multiplication. In HBsAg positive samples, DNA-P activity was positive in 44.4% of the HBV carriers, 52.9% of the patients with chronic active hepatitis and 81.8% of the patients with liver cirrhosis. The corresponding figures for the presence of HBeAg in these groups were 18.5, 26.5 and 45.5% respectively. Virus multiplication was also observed in 41.1 and 44.4% patients with chronic active hepatitis and liver cirrhosis respectively, in the absence of HBsAg. The results of the present study show that hepatitis B virus is the most important etiological factor of chronic liver diseases in India. Most of our patients of chronic liver diseases seems to have contacted HBV infection as young adults and the mode of transmission is likely to be horizontal rather than vertical. The virus replicating markers correlate well with the severity of the liver injury and decreased with the age. DNA-P activity is a more sensitive marker of viral multiplication than HBeAg. Viral multiplication was also found to occur in the absence of the usual HBV markers. Continued viral multiplication in patients with chronic active hepatitis and liver cirrhosis is implicated in continued liver injury and progressive liver disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347477     DOI: 10.1007/bf02776826

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  35 in total

1.  Chronic active hepatitis.

Authors:  L Krishnamurthy; D S Singh; H D Tandon; B N Tandon
Journal:  Indian J Med Res       Date:  1976-09       Impact factor: 2.375

2.  Markers of viral replication in patients with chronic hepatitis B virus infection.

Authors:  S Govindarajan; T L Fong; B Valinluck; V Edwards; A G Redeker
Journal:  Am J Clin Pathol       Date:  1988-02       Impact factor: 2.493

3.  Monoclonal antibodies as diagnostic probes in the etiology of hepatitis.

Authors:  E Ben-Porath; J R Wands
Journal:  Semin Liver Dis       Date:  1984-02       Impact factor: 6.115

4.  Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.

Authors:  Y F Liaw; C M Chu; I J Su; M J Huang; D Y Lin; C S Chang-Chien
Journal:  Gastroenterology       Date:  1983-02       Impact factor: 22.682

5.  A low cost micro-ELISA test for hepatitis-B surface antigen.

Authors:  B M Gandhi; B N Tandon
Journal:  Trop Gastroenterol       Date:  1984 Jul-Sep

6.  Natural history of chronic persistent hepatitis B. Relationship between hepatitis B virus replication and the course of the disease.

Authors:  J M Sánchez-Tapias; J H Vilar; J Costa; M Bruguera; A M Ballesta; J Rodés
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

7.  Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection.

Authors:  I J Su; M Y Lai; H C Hsu; D S Chen; P M Yang; S M Chuang; J L Sung
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

8.  Natural history of chronic hepatitis B virus-related liver disease and its relationship to serum markers of viral replication.

Authors:  R Williams; G J Alexander
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

9.  The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles.

Authors:  I V Weller; M J Fowler; J Monjardino; H C Thomas
Journal:  J Med Virol       Date:  1982       Impact factor: 2.327

10.  Hepatitis B virus DNA in asymptomatic HBsAg carriers: comparison with HBeAg/anti-HBe status.

Authors:  B Berris; R E Sampliner; R Sooknanan; S V Feinman
Journal:  J Med Virol       Date:  1987-11       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.